leisure time -WSS

leisure time

author：focus 2025-09-30 17:28:16 - browse：8114

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Illumina names Agilent executive as new CEO

WSS

Humana sues Biden admin over Medicare Advantage audit rule

'Make People Better': The CRISPR babies story you probably don't know

Illumina names Agilent executive as new CEO

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

The (many) problems with a new study criticizing cancer screening

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

knowledge

leisure time

explore

The high cost of giving birth even with insurance

What drug price negotiations mean for Medicare Part D

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Hollywood unions extend contract negotiations for actors

FDA's Woodcock to retire early next year

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Illumina names Agilent executive as new CEO

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Anthos stroke drug appears safer than common blood thinner

explore

Crinetics acromegaly drug succeeds in late

How to fix cancer clinical trials' diversity problem

Hospitals look to new technology to keep health care workers safe

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Illumina names Agilent executive as new CEO

Childhood cancer progress stalls for Black, Hispanic kids: Report

hotspot

Wikipedia

entertainment

hotspot